Seegnal to miss April 30 financial filing deadline

Mr. Elad Bibi-Aviv reports SEEGNAL INC. ANNOUNCES DELAY IN FILING 2025 ANNUAL FINANCIAL STATEMENTS Seegnal Inc. was unable to file its audited annual consolidated financial statements for the year ended Dec. 31, 2025, together with the related management discussion and analysis and chief executive officer and chief financial officer certifications, by the prescribed filing deadline of April 30, 2026. The delay is related to the timing required by the company's recently engaged external auditor to complete final internal procedures prior to issuing its audit opinion. In connection with the anticipated late filing, the company has applied to the Alberta Securities Commission, as principal regulator, and to the British Columbia Securities Commission and the Ontario Securities Commission for a management cease trade order (MCTO) in accordance with National Policy 12-203, Management Cease Trade Orders. If issued, the MCTO will prohibit trading in the company's securities by the company's chief executive officer and chief financial officer for so long as the order remains in effect. If issued, and during the period in which the MCTO is in effect, the general investing public will continue to be able to trade in the company's common shares listed on the TSX Venture Exchange. However, for the duration of the MCTO, the company's chief executive officer and chief financial officer will not be able to trade in the company's common shares, nor will the company be able to, directly or indirectly, issue securities to or acquire securities from an insider or employee of the company except in accordance with legally binding obligations to do so. The company confirms that it will comply with the alternative information guidelines set forth in NP 12-203 for so long as it remains in default of the requirement to file the annual filings. The company is not subject to any insolvency proceedings. The MCTO will remain in effect until the company files the annual filings or the MCTO is otherwise revoked or varied. About Seegnal Inc. Seegnal is a public company that aims to solve one of the top causes of death and injuries in the modern world -- adverse drug effects (ADEs). Seegnal's clinical decision support system introduces a paradigm shift in the approach to this problem by implementing a new elevated patient-centric standard. Seegnal's SaaS (software-as-a-service) technology exclusively integrates, at the point of care, unique patient-specific data such as genetics, results of lab tests, ECG (electrocardiogram), smoking, allergies, food, gender, age and the effects of many concomitant medications, while reducing the current alert load for clinicians by over 90 per cent. In practice, clinicians using Seegnal eHealth complete their prescription workflow with limited interruption, saving time and fatigue. Similarly, patients enjoy more tailored medication and improved safety, leading to better quality of life, due to the precision of alerts with up to 98-per-cent accuracy. Institutions reported a reduction in admissions, medication consumption and ample time savings in prescription renewals. Seegnal eHealth is marketing its SaaS-based platform in the state of Israel (where recently the Ministry of Health has adopted Seegnal's patient-specific standard as the new standard in governmental hospitals), the United Arab Emirates, the United Kingdom, the United States and Poland. The platform is currently a standard of care system for over 10,000 clinicians in Israel, used on a daily basis for prescribing medications to their patients. We seek Safe Harbor.